17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α is a synthetic derivative of prostaglandins, which are lipid compounds that play crucial roles in various physiological processes, including inflammation, blood flow, and the formation of blood clots. This specific compound features a trifluoromethyl group, which enhances its biological activity and stability. The presence of the trinor structure indicates modifications that reduce the size of the molecule while retaining its functional properties. The dihydro modification suggests that it has undergone hydrogenation, affecting its reactivity and interaction with biological targets. As a prostaglandin analog, it may exhibit potent effects on smooth muscle contraction and vasodilation, making it of interest in pharmacological research. Its unique chemical structure contributes to its potential therapeutic applications, particularly in areas related to cardiovascular health and reproductive biology. However, detailed studies on its pharmacokinetics, efficacy, and safety profile would be necessary to fully understand its potential uses in medicine.

A number of 17-
aryl trinor and 16-
aryloxy tetranor prostaglandin F
2α
derivatives have been approved for the treatment of glaucoma.
1
,
2
,
3
These “ring” prostaglandin (PG) analogs have improved efficacy over the PGs with an n-
alkyl lower side chain. Of these, the ones wherein the 13,14-
double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects.
4
17-
trifluoromethylphenyl-
13,14-
dihydro trinor PGF
1α
(17-
TFM-
PGF
1α
) is a typical “ring” analog reminiscent of the trifluoromethyl-
phenoxy ring of Travoprost. The a chain of 17-
TFM-
PGF
1α
is saturated, making this compound a formal member of the one-
series PGs. Recent work has shown that in the “ring” series of analogs, this modification has little impact on FP receptor binding.
5
As an ocular hypotensive agent, it is expected that 17-
TFM-
PGF
1α
would act very much like the free acid of latanoprost.

17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α

1027401-98-4: 17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α is a synthetic derivative of prostaglandins, which are lipid compounds that play crucial roles in various physiological processes, including inflammation, blood flow, and the formation of blood clots. This specific compound features a trifluoromethyl group, which enhances its biological activity and stability. The presence of the trinor structure indicates modifications that reduce the size of the molecule while retaining its functional properties. The dihydro modification suggests that it has undergone hydrogenation, affecting its reactivity and interaction with biological targets. As a prostaglandin analog, it may exhibit potent effects on smooth muscle contraction and vasodilation, making it of interest in pharmacological research. Its unique chemical structure contributes to its potential therapeutic applications, particularly in areas related to cardiovascular health and reproductive biology. However, detailed studies on its pharmacokinetics, efficacy, and safety profile would be necessary to fully understand its potential uses in medicine.

17-TFM-PGF1α (Compound 8) is a saturated prostaglandin analog. It exhibits a high affinity and receptor selectivity for the human prostaglandin F receptor (hFP receptor), with an EC50 of 85 nM.

CAS 1027401-98-4

17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α

17-TFM-PGF1α

Ref: TM-T203103